New Insight for HBV DNA and HBsAg Quantitation during Antiviral Therapy in Patients with Chronic Hepatitis B / 대한소화기학회지
The Korean Journal of Gastroenterology
;
: 144-149, 2011.
Artículo
en Coreano
| WPRIM
| ID: wpr-151920
ABSTRACT
Over the past decade, advances in the antiviral therapy in patients with chronic hepatitis B have enabled the sustained suppression of hepatitis B viral replication and the prevention of progressive liver disease. Hepatitis B surface antigen (HBsAg) has been used to diagnose patients with hepatitis B virus infection. Recently, test for quantitative HBsAg titers are available and on-treatment HBsAg quantitations are used to predict treatment outcome. Serum HBV DNA levels have been shown to predict natural course of chronic hepatitis B infection. The HBV DNA levels have been reported to be positively correlated with the development of cirrhosis, hepatocellular carcinoma and related death. The baseline and on-treatment levels of HBV DNA are important factors for predicting treatment outcomes. In this article, we will discuss the role of HBV DNA and HBsAg quantitation during antiviral therapy.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Antivirales
/
Pirimidinonas
/
ADN Viral
/
Virus de la Hepatitis B
/
Carcinoma Hepatocelular
/
Lamivudine
/
Hepatitis B Crónica
/
Antígenos de Superficie de la Hepatitis B
/
Cirrosis Hepática
/
Neoplasias Hepáticas
Tipo de estudio:
Estudio pronóstico
Límite:
Humanos
Idioma:
Coreano
Revista:
The Korean Journal of Gastroenterology
Año:
2011
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS